Q-omics provides the consensus-scored HSFY3P profile across patient tissues and cancer cell-line models. HSFY3P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, HSFY3P is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, HSFY3P RNA expression shows 5,632 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and KICH as cancer lineages where HSFY3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSFY3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSFY3P survival associations across molecular data types. HSFY3P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSFY3P RNA expression–survival associations across cancer types. High HSFY3P expression shows unfavorable associations in STAD, THCA and DLBC, but favorable associations in UVM, THYM and PAAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for HSFY3P RNA expression.
This table summarizes HSFY3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for HSFY3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSFY3P shows lower tumor expression in KICH, PAAD and KIRP and higher tumor expression in HNSC and CHOL. The KICH box plot shows higher HSFY3P RNA expression in normal versus tumor tissue (log2 FC = −0.053, t-test p < 0.001).
This table shows molecular features associated with HSFY3P in patient tissues and cancer cell lines. In patient samples, HSFY3P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
